OVERVIEW
new edition of this best-selling reference for oncology professionals!

The updated Sixth Edition of Pocket Guide to Chemotherapy Protocols continues the success of previous editions by supplying physicans, nurses, and other healthcare providers with the authoritative information they need in one easy-to-use guide. Spiral bound and arranged alphabetically by cancer type, Pocket Guide to Chemotherapy Protocols, Sixth Edition allows for quick reference. This compact text contains combination as well as selected single-agent regimens for solid tumors and hematologic malignancies. Regimens are selected based on published literature and their use in clinical practice in medical oncology. Evidence-based, up-to-date, and comprehensive, Pocket Guide to Chemotherapy Protocols, Sixth Edition is an invaluable guide for every oncology professional!

ABOUT THE AUTHOR

Edward Chu, MD - Yale University School of Medicine, New Haven, Connecticut

Dr. Edward Chu is Professor of Medicine and Pharmacology at the Yale University School of Medicine. He received his M.D. degree from Brown University, where he also completed his residency training in Internal Medicine Residency. He then went to the National Cancer Institute in Bethesda, MD for fellowship training in Medical Oncology. Following completion of his fellowship, he remained at the NCI as a Senior Clinical Investigator. In 1996, he was recruited to the Yale Cancer Center of the Yale University School of Medicine where he assumed the positions of Director of the VACT Cancer Center, Associate Director of the Yale Cancer Center, and he is co-Director of the Developmental Therapeutics Program at the Yale Cancer Center.

Dr. Chu is well-known for his basic research that has investigated the determinants of resistance to the fluoropyrimidine class of anticancer agents. In particular, his group has made seminal observations on the regulation of expression of thymidylate synthase, a critical target in cancer chemotherapy, with specific focus on elucidating novel translational regulatory mechanisms. In addition, his group is actively involved in developing novel compounds and strategies for the treatment of colorectal cancer as well as other human malignancies. He has worked closely with a number of drug companies to develop novel agents, and these companies include Roche, Bristol-MyersSquibb, Astra Zeneca, Eli Lilly, Pharmacia, GlaxoSmithKline, Imclone, Vion, and Tularik. He serves on the scientific advisory boards of Advrx Pharmaceuticals, Celator, Etex, Phytoceutica, and Eximias, all of which are drug development companies.

He is the author of the Physicians’ Cancer Chemotherapy Drug Manual, which is now in its sixth edition, and this drug manual includes a comprehensive review of all of the main drugs and drug regimens currently used in clinical practice for oncology. He is the founding Editor-in-Chief of the clinical journal Clinical Colorectal Cancer and is the Chairman of the International Colorectal Congress, which is an annual international meeting focusing on management and treatment of colorectal cancer.